CJC-1295 + Ipamorelin (GHRH Analog and GHRP Combination)

The CJC-1295 + Ipamorelin combination is a synergistic growth hormone–releasing peptide system that integrates two complementary mechanisms to enhance endogenous GH secretion and IGF-1 production. This pairing is designed to mimic the natural pulsatile release of growth hormone while minimizing desensitization and hormonal imbalance.

Mechanistic Overview:

• CJC-1295: A synthetic GHRH analog modified with a Drug Affinity Complex (DAC) to extend its plasma half-life. It binds to GHRH receptors on pituitary somatotrophs, activating the adenylate cyclase–cAMP pathway to stimulate GH synthesis and release. The DAC modification allows for prolonged receptor activation and sustained GH elevation, leading to enhanced protein synthesis, lipid metabolism, and cellular repair.

• Ipamorelin: A selective growth hormone secretagogue receptor (GHS-R1a) agonist, acting on ghrelin receptors to trigger GH release via the phospholipase C (PLC)/IP₃–Ca²⁺ pathway. Unlike earlier GHRPs, Ipamorelin exhibits high receptor selectivity, producing GH stimulation with minimal effects on cortisol or prolactin levels.

Combined Biological Effects: The concurrent use of CJC-1295 and Ipamorelin produces amplified GH pulsatility through dual receptor activation — GHRH and GHS-R — resulting in elevated IGF-1 levels, improved body composition, muscle recovery, and metabolic regulation. The combination mimics physiological GH release more closely than either peptide alone, supporting homeostatic balance within the somatotropic axis.

Applications:

• Research on growth hormone dynamics and pituitary regulation

• Studies of metabolic and anabolic signaling via GH/IGF-1 pathways

• Investigations into recovery, cellular regeneration, and anti-aging physiology